Program
tucatinib
Also written as “Tucatinib”, “Tucatinib (ONT-380)” and “ARRY-380, HER2 inhibitor; oral”.
Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Uterine Cervical Neoplasms · Adenocarcinoma Of Esophagus · Neoplasms, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 218 open or running | phase 4since Aug 12, 2026 | Mar 31, 2008 | Dec 31, 2026phase 1 · NCT05382364 |
| Criterium | 22 open or running | phase 2since Dec 27, 2021 | Dec 27, 2021 | Jun 1, 2027phase 2 · NCT05458674 |
| AstraZeneca | 11 open or running | phase 2since Aug 31, 2020 | Aug 31, 2020 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 2since Nov 12, 2020 | Nov 12, 2020 | none ahead |
Also a collaborator on its studies: Novartis.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Mar 31, 2008.
- Jun 4, 2019Phase 3 study in HER2-positive Breast CancerPfizer · NCT03975647 · 466 enrolled · United States, Australia, Austria and more
- Jun 10, 2020Phase 2 study in Colorectal NeoplasmsPfizer · NCT04430738 · 40 enrolled · United States, Japan
- Jul 31, 2020Phase 3 study in Adenocarcinoma Of EsophagusPfizer · NCT04499924 · 17 enrolled · United States, Australia, Canada and more
- Aug 31, 2020Phase 2 study in Breast NeoplasmsPfizer · NCT04539938 · 70 enrolled · United States
- Aug 31, 2020AstraZeneca's first study: phase 2 study in Breast NeoplasmsNew to AstraZenecaAstraZeneca · NCT04538742 · 245 enrolled · United States, Australia, Brazil and more
- Oct 1, 2020Phase 2 study in Uterine NeoplasmsPfizer · NCT04579380 · 217 enrolled · United States, Belgium, Germany and more
- Nov 12, 2020Hoffmann-La Roche's first study: phase 2 study in Advanced Unresectable or Metastatic Solid MalignancyNew to Hoffmann-La RocheHoffmann-La Roche · NCT04632992 · 252 enrolled · United States
- Jan 20, 2021Phase 2 study in Breast NeoplasmsPfizer · NCT04721977 · 66 enrolled · Japan, South Korea, Taiwan
- Nov 12, 2021Phase 3 study in Breast NeoplasmsPfizer · NCT05132582 · 654 enrolled · United States, Australia, Austria and more
- Dec 27, 2021Criterium's first study: phase 2 study in HER2-positive Metastatic Breast CancerNew to CriteriumCriterium · NCT05230810 · 40 enrolled · United States
- Feb 14, 2022Phase 3 study in Colorectal NeoplasmsPfizer · NCT05253651 · 400 enrolled · United States, Argentina, Australia and more
- May 16, 2022Phase 1 study in Breast NeoplasmsPfizer · NCT05382364 · 25 enrolled · China
- Jun 27, 2022Phase 2 study in Breast NeoplasmsCriterium · NCT05458674 · 17 enrolled · United States
- Aug 12, 2026Phase 4 study in Uterine Cervical NeoplasmsPfizer · NCT07768358 · 175 planned
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Breast NeoplasmsPfizer · NCT05382364
- Jun 1, 2027Primary completion: phase 2 study in Breast NeoplasmsCriterium · NCT05458674
- Dec 31, 2027Primary completion: phase 3 study in Colorectal NeoplasmsPfizer · NCT05253651
- Mar 13, 2032Primary completion: phase 4 study in Uterine Cervical NeoplasmsPfizer · NCT07768358
TargetBeta
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07768358Uterine Cervical Neoplasms | 4 | Not yet recruiting | Pfizer | Mar 13, 2032 | 175 |
| NCT05458674Breast Neoplasms · United States | 2 | Active, not recruiting | Criterium | Jun 1, 2027 | 17 |
| NCT05382364Breast Neoplasms · China | 1 | Active, not recruiting | Pfizer | Dec 31, 2026 | 25 |
| NCT05253651Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Dec 31, 2027 | 400 |
| NCT05230810HER2-positive Metastatic Breast Cancer · United States | 2 | Active, not recruiting | Criterium | Mar 30, 2026 | 40 |
| NCT05132582Breast Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Pfizer | Sep 5, 2025 | 654 |
| NCT04721977Breast Neoplasms · Japan, South Korea, Taiwan | 2 | Active, not recruiting | Pfizer | Jul 17, 2023 | 66 |
| NCT04632992Advanced Unresectable or Metastatic Solid Malignancy · United States | 2 | Completed | Hoffmann-La Roche | Dec 4, 2023 | 252 |
| NCT04579380Uterine Neoplasms · United States, Belgium, Germany and more | 2 | Active, not recruiting | Pfizer | Nov 1, 2023 | 217 |
| NCT04539938Breast Neoplasms · United States | 2 | Completed | Pfizer | Jul 15, 2024 | 70 |
| NCT04538742Breast Neoplasms · United States, Australia, Brazil and more | 2 | Active, not recruiting | AstraZeneca | Jan 31, 2025 | 245 |
| NCT04499924Adenocarcinoma Of Esophagus · United States, Australia, Canada and more | 3 | Completed | Pfizer | Apr 17, 2024 | 17 |
| NCT04430738Colorectal Neoplasms · United States, Japan | 2 | Active, not recruiting | Pfizer | Jul 31, 2024 | 40 |
| NCT03975647HER2-positive Breast Cancer · United States, Australia, Austria and more | 3 | Active, not recruiting | Pfizer | Jun 29, 2023 | 466 |
| NCT03914755Healthy · United States | 1 | Completed | Pfizer | Aug 4, 2019 | 36 |
| NCT03826602Drug-drug Interaction · United States | 1 | Completed | Pfizer | Mar 8, 2019 | 18 |
| NCT03777761Healthy · United States | 1 | Completed | Pfizer | Mar 11, 2019 | 55 |
| NCT03758339Healthy · United States | 1 | Completed | Pfizer | Jan 30, 2018 | 8 |
| NCT03723395Drug-drug Interaction · United States | 1 | Completed | Pfizer | Dec 21, 2018 | 116 |
| NCT03722823Hepatic Impairment · United States | 1 | Completed | Pfizer | May 7, 2019 | 37 |
| NCT03043313Colorectal Neoplasms · United States, Belgium, France and more | 2 | Completed | Pfizer | Mar 28, 2022 | 117 |
| NCT02614794Breast Neoplasms · United States, Australia, Austria and more | 2 | Completed | Pfizer | Sep 4, 2019 | 612 |
| NCT02025192Breast Neoplasms · United States | 1 | Completed | Pfizer | Oct 3, 2017 | 60 |
| NCT01983501Breast Neoplasms · United States, Canada | 1 | Completed | Pfizer | Oct 10, 2017 | 57 |
| NCT00650572Neoplasms · United States, Canada | 1 | Completed | Pfizer | Mar 2013 | 50 |
How it is read
Names in the registry
- “Tucatinib”, 12 entries
- “tucatinib”, 11 entries
- “Tucatinib (ONT-380)”, 1 entry
- “ARRY-380, HER2 inhibitor; oral”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 11 studies
- Colorectal Neoplasms, 3 studies
- Uterine Cervical Neoplasms, 2 studies
- Adenocarcinoma Of Esophagus, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.